Dataset related to the article "Angiogenic and reparative potency of a human cardiac CD90- mesenchymal subpopulation in heart ischemic model"

This record contains raw data related to the article “Angiogenic and reparative potency of a human cardiac CD90- mesenchymal subpopulation in heart ischemic model”. Background: Despite recent significant therapeutic progress, cardiovascular diseases (CVD) remain an unmet clinical, economic, and social burden worldwide. Cell-based therapies have been proposed as therapeutic strategies, however, the overall efficacy was modest. Objective: We aimed to fully characterize a novel subpopulation of CD90- mesenchymal cells derived from human heart tissue (hCmPC90-) and evaluate its ability to induce cardiac tissue repair and functional recovery. Methods: We performed a comprehensive phenotypic characterization of the hCmPC90- by flow cytometry and RNA sequencing. A direct comparison of hCmPC90- with previously clinically tested bone marrow- and cardiac-derived cell types, has been conducted both in vitro by means of various assays of angiogenic potency, and in vivo, by testing the ability to ameliorate left ventricular function in a mouse model of acute myocardial infarction (AMI). Results: hCmPC90- showed distinct surface markers and transcriptional phenotype compared with unselected mesenchymal heart cells (hCmPCs) and the positive CD90 counterpart (hCmPC90+). When human hCmPC90-, hCmPC90+, hCmPC, cardiosphere-derived cells (CDCs), and bone marrow-derived CD34+ cells were functionally tested in vitro, hCmPC90- revealed a superior endothelial differentiation ability, higher anti-inflammatory, cardio-protective capacity, and angiocrine activity. Moreover, hCmPC90- showed specific immune-privileged features. When intramyocardially delivered into infarcted mouse hearts , hCmPC90- outperformed three weeks after injection other clinical-grade cell types, as for left ventricular (LV) function and adverse LV remodeling recovery, infarct size reduction, and vascular density augmentation. Conclusion: hCmPC90- shows a superior biological potency which deserves clinical exploitation as an advanced therapy medicinal product in the context of refractory ischemic heart disease. This dataset is not public. It’s available upon reasonable requesto to the corresponding author.本数据集包含与论文《人心脏CD90阴性间充质亚群在心脏缺血模型中的血管生成与修复潜能》相关的原始实验数据。 背景：尽管近期治疗学取得显著进展，心血管疾病（cardiovascular diseases, CVD）仍是全球范围内尚未被满足的临床、经济与社会负担。基于细胞的治疗方案已被提出作为治疗策略，但整体疗效有限。 研究目的：本研究旨在全面表征源自人心脏组织的新型CD90阴性间充质细胞亚群（hCmPC90⁻），并评估其诱导心脏组织修复与功能恢复的能力。 研究方法：本研究通过流式细胞术与RNA测序（RNA sequencing）对hCmPC90⁻进行全面的表型表征。此外，将hCmPC90⁻与此前已进入临床测试的骨髓来源及心脏来源细胞类型进行直接对比：体外实验采用多种血管生成潜能检测方法，体内实验则通过在急性心肌梗死（acute myocardial infarction, AMI）小鼠模型中评估其改善左心室功能的能力。 研究结果：与未分选的心脏间充质细胞（hCmPCs）以及CD90阳性对应亚群（hCmPC90⁺）相比，hCmPC90⁻具有独特的表面标志物与转录组表型。在体外功能验证实验中，分别对hCmPC90⁻、hCmPC90⁺、hCmPC、心脏球来源细胞（cardiosphere-derived cells, CDCs）以及骨髓来源CD34阳性细胞（CD34+ cells）进行检测，结果显示hCmPC90⁻具有更优异的内皮分化能力、更强的抗炎与心脏保护能力，以及更高的血管分泌活性。此外，hCmPC90⁻还具备特定的免疫豁免特性。当将hCmPC90⁻通过心肌内注射植入梗死小鼠心脏后，注射三周时，其在改善左心室（left ventricular, LV）功能与不良左心室重构恢复、缩小梗死面积以及增加血管密度方面，均优于其他临床级细胞类型。 研究结论：hCmPC90⁻具有更优异的生物学潜能，有望作为难治性缺血性心脏病领域的先进治疗药物（advanced therapy medicinal product）开展临床转化研究。 本数据集暂未公开，若有合理请求可向通讯作者申请获取。